The size of the mycoplasma testing market in the Middle East and Africa is predicted to worth USD 95.09 Million by 2027 and USD 64.03 Million in 2022, growing at a CAGR of 8.23% from 2022 to 2027.
Factors such as growing spending by biopharmaceutical companies on R&D, increasing government initiatives and research funding, technological advancements, growing demand for rapid, accurate, and affordable tests, and increasing contamination of cell cultures further stimulate the MEA mycoplasma testing market. Furthermore, contamination by mycoplasmas is responsible for developing toxins and alterations in the formation of metabolites in cell culture. Hence, it plays a vital role in the biopharmaceutical industries.
The growth of the MEA mycoplasma testing market is further driven by the growth of the biotechnology and pharmaceutical sector. Moreover, an increase in the contamination of cultures, technological advancements, and increased investments by organizations in research and development activities contributes to the growth of the mycoplasma testing market.
The high cost of the instruments and keeping the instruments in proper storage condition is expected to restrain the market's growth during the forecast period. In addition, there are some strict government regulations in several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major impediments to the growth of the MEA mycoplasma testing market.
The prevalence of mycoplasma pneumonia co-infection in COVID-19 patients is expected to drive the market for mycoplasma testing during the forecast period. In addition, the presence of M. pneumonia co-infection increases the need to test patients for COVID-19, increasing the demand for routine diagnostic tests for respiratory pathogens such as M. pneumonia.
Co-infections in COVID-19 cases have a significant likelihood of being caused by Mycoplasma disease. For example, according to a 2020 study published in the Archives of Medical Laboratory Sciences, co-infection with M. pneumonia ranged from 1% to 44.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae. Infection among COVID-19 patients was reported by 19%.
Mycoplasma easily spreads through droplets during cell culture and can survive in a dry form for months. Mycoplasma contamination is difficult to see under a microscope and requires specific tests to be detected. Contamination can have an immense impact on the experimental work hence is technique sensitive and require skilled workers.
This research report on the Latin America Mycoplasma Testing Market has been segmented and sub-segmented into the following categories:
Geographically, the Middle East is expected to grow at a healthy growth rate owing to its well-established healthcare industry and the increasing prevalence of chronic diseases in the region. Saudi Arabia is expected to play a leading role in the Middle East and Africa market due to the rise in prevalence of mycoplasma infections amongst young children in the region. Other growth factors in this region are global biotechnology companies and pharmaceutical players and increased investment. In addition, due to increasing technological advancements in cell culture and government-funded development assistance for drug research, growth is seen in populated areas such as South Africa, Kuwait, and the United Arab Emirates.
While less developed regions such as North Africa and Turkey are expected to show comparatively lower growth, this is due to rising healthcare expenditure and rapid, sensitive testing.
KEY MARKET PLAYERS:
PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, and WuXi AppTec are a few of the notable companies in the MEA mycoplasma testing market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org